Microbiome, Clinical Trial Enrichment Among Question Marks As US FDA Weighs Guidance On Non-Traditional Infectious Disease Treatment
Discussions among panelists at US FDA meeting reveal lack of consensus in many key areas.
Discussions among panelists at US FDA meeting reveal lack of consensus in many key areas.